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Background: Population- based serologic studies are a vital tool for understanding the 
epidemiology of influenza and other respiratory viruses, including the early assess-
ment of the transmissibility and severity of the 2009 influenza pandemic, and Middle 
East respiratory syndrome coronavirus. However, interpretation of the results of sero-
logic studies has been hampered by the diversity of approaches and the lack of stand-
ardized methods and reporting.
Objective: The objective of the CONSISE ROSES-I statement was to improve the qual-
ity and transparency of reporting of influenza seroepidemiologic studies and facilitate 
the assessment of the validity and generalizability of published results.
Methods: The ROSES- I statement was developed as an expert consensus of the CON-
SISE epidemiology and laboratory working groups. The recommendations are pre-
sented in the familiar format of a reporting guideline. Because seroepidemiologic 
studies are a specific type of observational epidemiology study, the ROSES- I state-
ment is built upon the STROBE guidelines. As such, the ROSES- I statement should be 
seen as an extension of the STROBE guidelines.
Results: The ROSES-I statement presents 42 items that can be used as a checklist of 
the information that should be included in the results of published seroepidemiologic 
studies, and which can also serve as a guide to the items that need to be considered 
during study design and implementation.
Conclusions: We hope that the ROSES- I statement will contribute to improving the 
quality of reporting of seroepidemiologic studies.
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CONSISE statement on the reporting of Seroepidemiologic 
Studies for influenza (ROSES- I statement): an extension of the 
STROBE statement
Peter W. Horby1 | Karen L. Laurie2 | Benjamin J. Cowling3 | Othmar G. Engelhardt4 |  
Katharine Sturm-Ramirez5 | Jose L. Sanchez6 | Jacqueline M. Katz5 | Timothy M. Uyeki5 |  
John Wood4,‡ | Maria D. Van Kerkhove7 | on behalf of the CONSISE Steering Committee*
1  | BACKGROUND
For all pathogens, cases of symptomatic illness from infections that are 
detected through routine healthcare statistics, laboratory networks, or 
other surveillance and reporting systems are only a small proportion of 
infections affecting a population. Relying on case incidence detected 
by this information alone can lead to large underestimates of infec-
tion rates and overestimates of severity of illness among the general 
population.1 Prior to, or during the early stages of epidemics, serologic 
testing of affected populations can provide valuable information on 
the proportion of the population that have a low titer of cross- reactive 
*CONSISE Steering Committee members are listed in Appendix 1.
‡Retired.
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antibodies and may be at higher risk of infection with pathogens for 
which the primary determinant of protection is humoral immunity, for 
example, influenza viruses. During later stages of epidemics, or follow-
ing epidemics, serologic testing can permit estimation of the number 
of infections that have occurred among the general population, which 
is important for determining important epidemiologic parameters, 
including the pathogen’s transmissibility, the proportion of the popu-
lation that remains susceptible to infection in subsequent epidemics, 
and the risk of severe disease or death conditional on infection. In the 
last decade, over 8000 studies have been published that are indexed 
with the Medical Subject Heading (MeSH) term “Seroepidemiologic 
Studies.” Approximately 500 studies of these are indexed with MeSH 
terms “Seroepidemiologic Studies” AND “influenza.”
The 2009 H1N1 influenza pandemic is an excellent example of 
how a variety of seroepidemiologic studies provided vital informa-
tion to supplement what was available from clinical and laboratory 
surveillance data.2–4 Severity of the 2009 H1N1 pandemic was ini-
tially overestimated from the reports of high risks of severe disease 
among critically ill patients in adult intensive care units in Mexico City 
and Winnipeg.5,6 However, inconsistencies in the reporting and stan-
dardization of both survey and laboratory methods have limited the 
comparability of results of 2009 H1N1 pandemic influenza seroepide-
miologic studies.7,8 Debate has also arisen around the interpretation 
of seroepidemiologic studies of avian influenza A virus (AIV) infections 
of humans, given uncertainties about assay performance and anti-
body kinetics in exposed and unexposed populations.9–11 In addition, 
new immunoassays and modifications of well- established assays are 
increasingly being used for the detection of influenza virus strain- 
specific antibodies.12–18 These issues led to the formation in 2010 of 
the Consortium for the Standardization of Influenza Seroepidemiology 
(CONSISE).19 CONSISE is comprised of international scientists experi-
enced in conducting seroepidemiologic studies of influenza and other 
emerging respiratory viruses; two working groups on epidemiology and 
laboratory matters were formed to provide tools to help standardize 
protocols and laboratory methods used (see https://consise.tghn.org/
about/working-group-projects/). The overarching goal of CONSISE is 
to improve the quality of data arising from influenza seroepidemiologic 
studies, harmonize methods used in such studies, and thereby provide 
better evidence for policy makers that guides rational implementation 
of intervention and control measures.19
Guidelines for the reporting of the design, conduct, and results 
of research have been an effective tool for improving the quality and 
interpretability of published data. Examples include the Consolidated 
Standards of Reporting Trials (CONSORT) and the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE).20,21 
These guidelines have become, in some instances, widely accepted 
standards for reporting of research studies, and the expectation that 
publications should meet these standards has helped to improve the 
design and conduct of studies. CONSISE has prepared the following 
statement, Reporting Of Sero- Epidemiologic Studies for Influenza 
(ROSES- I), which distills the experience of the working groups into 
a set of recommendations on the optimal reporting of influenza 
 seroepidemiologic studies.
1.1 | Objective
The aim of the CONSISE ROSES- I statement was to improve the qual-
ity and transparency of reporting of seasonal, avian, and pandemic 
influenza seroepidemiologic studies in order for the validity and gen-
eralizability of the results to be better assessed. This statement also 
aims to improve the design and conduct of influenza seroepidemiolog-
ic studies by proposing reporting standards that investigators should 
consider when designing studies. CONSISE has developed a number 
of protocols as guides to the design and implementation of seroepi-
demiologic studies, and these protocols (available at https://consise.
tghn.org/articles/available-consise-influenza-protocols/) are a valu-
able resource that should be consulted in addition to the ROSES- I 
statement (Table 1).
The components of the ROSES- I statement can be used as a 
checklist to help guide what key information should be included in the 
results of published seroepidemiologic studies, and can also serve as a 
guide to the items that need to be considered during study design and 
implementation. As with other reporting guidelines, this statement is 
not intended as a required framework that must be followed in con-
tent and format. It is also not designed as an instrument for assessing 
study quality, for which other instruments exist22,23.
2  | METHODS
The need for the ROSES- I statement was agreed at the 4th 
International CONSISE meeting held on September 3–4, 2013, in 
Cape Town, South Africa.24 The ROSES- I statement constitutes an 
expert consensus on the key information that should be considered 
when reporting the results of seroepidemiologic investigations of 
influenza and other emerging viruses in order for the validity and 
generalizability of the results to be assessed by third parties, and 
to allow comparisons and inferences across study populations. This 
statement consolidates the recommendations of the CONSISE epi-
demiology and laboratory working groups into the familiar format 
of a reporting guideline. It was developed by CONSISE members 
(PH, BC, JW, OE, KLL, MVK) with input by the CONSISE Steering 
Committee and other CONSISE members. Because seroepidemio-
logic studies are a specific kind of observational study, this ROSES- I 
statement has built upon the STROBE guidelines in order to avoid 
confusion and conflicts. As such, the ROSES- I statement should be 
seen as an extension of the STROBE guidelines, in the same way 
that the STrengthening the REporting of Genetic Association Studies 
(STREGA) guidelines are an extension of STROBE for gene–disease 
association studies.25
2.1 | Search strategy and selection criteria
References for this review were identified through a search of 
PubMed conducted on May 15, 2014, and updated in May 2015 
using the term (“Seroepidemiologic Studies”[Mesh] AND “Influenza, 
Human”[Mesh]). The title and abstract of 255 articles published in 
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TABLE  1 Seroepidemiologic investigation templatesa by CONSISE
Available protocola Primary objectives Strengths Weaknesses
Importance of timing of 
sampling
Pandemic influenza or novel/emerging respiratory viruses
Prospective longitudinal 
cohort study of 
influenza virus 
infections
Estimate age- specific 
incidence rates and 
cumulative incidence of 
infections during an 
influenza epidemic
Provides age- specific 
rates, monitors ongoing 
transmission rates, uses 
matched serum samples 
from enrolled partici-
pants, can measure the 
asymptomatic infection 
rates
Resource intensive, loss to 
follow up if closed 
cohort; limited time for 
initial recruitment and 
completion of baseline 
sample collection
Important: baseline before 
epidemic or as soon as 
possible. Follow- up can 
be anytime after 
epidemic
Cross- sectional 
seroprevalence study 
of a novel influenza A 
virus infection prior to 
and post- outbreak or 
post- epidemic periods
Estimate age- specific 
cumulative incidence of 
infection with a novel 
influenza A virus in the 
population 
Estimate prevalence of 
cross- reactive antibodies 
to the novel virus among 
exposed persons and 
general population
Provides the same 
age- related immunity 
estimates as longitudinal 
study; less resource- 
intensive than longitudi-
nal study; no concern 
about loss to follow up; 
select the specific age 
groups to target
Cannot follow the same 
participants as longitudi-
nal study; increased risk 
for bias and interperson 
variability; may not be 
matched for location or 
population makeup; 
cannot measure 
asymptomatic infection 
rates
Important: baseline before 
epidemic or as soon as 
possible. Follow- up can 
be anytime after 
epidemic
Household transmission 
studies of influenza
Estimate household 
secondary infection risk, 
and factors associated 
with variation in the 
secondary infection risk 
Characterize secondary 
cases including clinical 
presentation and 
asymptomatic fraction 
Investigate humoral 
immune response by 
serology following 
confirmed influenza virus 
infection
Provides age- specific 
rates, monitors ongoing 
transmission rates, uses 
serial serum samples 
from enrolled partici-
pants, can measure the 
asymptomatic infection 
rate as well as clinical 
severity and duration; 
can measure duration of 
infectiousness; can 
measure secondary rate 
of infection; can test 
effectiveness of 
interventions
The most resource- 
intensive study design; 
loss to follow up if closed 
cohort; need to recruit 
during widespread 
circulation in community; 
challenges in the 
selection of participating 
households
Important: baseline before 
epidemic or as soon as 
possible. Follow- up 
required after every 
illness episode within the 
household
Closed settings (e.g., 
military, child or elderly 
care centers, prisons) 
outbreak investigation 
protocol for influenza 
or novel respiratory 
virus
Describes the clinical 
spectrum of infection 
including the asympto-
matic fraction 
Estimate overall clinical 
attack rates (by subgroup 
and clinical risk group) 
Describe the correlation 
between infection, 
disease, and detection of 
antibodies by serology
Provides age- specific 
rates, monitors ongoing 
transmission rates, serial 
serum samples from 
enrolled participants, can 
measure the asympto-
matic infection rate as 
well as clinical severity 
and duration; can 
measure the duration of 
infectiousness; can 
measure the secondary 
rate of infection; test the 
effectiveness of 
interventions
Not as generalizable as it 
targets specific groups at 
risk; may give only 
restricted age group 
information; may not be 
totally closed setting 
(e.g., visitors, outings); 
length of stay in study 
setting may not span the 
whole epidemic period
Important: baseline before 
epidemic or as soon as 
possible. Follow- up 
required after every 
illness episode within the 
setting
Assessment of influenza 
virus infection in 
healthcare personnel
Detect evidence of 
human- to- human 
transmission of a novel 
influenza A virus within a 
healthcare setting
Identifies occupational 
risks of transmission and 
acquisition of infectious 
agent; assesses 
interventions targeting 
healthcare providers; low 
rates of loss to follow up
Not as generalizable as it 
targets only healthcare 
providers; may not be 
totally closed setting; 
may need to be tailored 
for pathogen- specific 
characteristics
Sera can be collected 
anytime depending upon 
emergence or prevalence 
of virus of interest
(Continues)
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English were reviewed and information from relevant studies was 
included in the review. Individual seroepidemiologic studies are ref-
erenced only where they demonstrate a principal of relevance to the 
ROSES- I reporting standards.
The ROSES- I standards comprise a checklist of items that should 
be addressed in addition to the STROBE items, or are suggested 
refinements of STROBE items, which are specifically applicable to 
seroepidemiologic studies. Where the existing STROBE item covers 
the issue in full and no specific addition or refinement is required for 
seroepidemiologic studies, the STROBE item is given in tables, but 
there is no corresponding ROSES- I item.
3  | RESULTS
3.1 | ROSES- I standards
3.1.1 | Title and abstract
To facilitate the clear identification of studies that quantitatively 
measure antibodies concentration in members of a defined popula-
tion in order to make inferences about exposure of that population 
to emerging respiratory viruses, transmission, and severity, one of 
the terms “seroepidemiologic,” “seroepidemiology,” “seroprevalence,” 
or “seroincidence” should be used in the title and/or abstract of the 
study, and the MeSH term “Seroepidemiologic Studies” should be 
used as a keyword [ROSES- I 1.1] (Table 2).
3.1.2 | Introduction
The validity of inferences about virus infection risks based on serology 
is dependent upon knowledge of the kinetics of antibody respons-
es following virus infection and of the performance of the antibody 
detection assay. The introduction should provide background infor-
mation justifying the choice of antibody detection assay and thresh-
olds for specific antibody titer or changes in antibody titer, which 
may be indicative of prior or recent infection [ROSES- I 2.1 and 2.2]. 
Depending on their design, seroepidemiologic studies can provide 
data on a variety of measures of the frequency of an outcome in the 
study population. For example, cross- sectional seroepidemiologic 
studies provide estimates of the point prevalence of different titers 
of antibodies, which are used as markers of prior infection (or vac-
cination) and may indicate the current level of antibody- mediated 
protection against infection with antigenically similar viruses if pro-
tective thresholds or correlates of protection have been established. 
The wording “seroprevalence at an antibody titer of ….” is preferred 
to “infection,” because antibody titers are dynamic, initially rising 
and then generally declining during variable periods after infection, 
and therefore, different assumptions underlie inferences about prior 
infection from antibody concentrations. Serological testing of paired 
serum specimens provides estimates of the cumulative incidence of 
virus infection (or incidence proportion). Serial cross- sectional or pro-
spective longitudinal cohort studies can be used to estimate cumula-
tive incidence of virus infection.4 Serology can also be used in studies 
Available protocola Primary objectives Strengths Weaknesses
Importance of timing of 
sampling
Seasonal influenza viruses
Seroepidemiology of 
human influenza A or B 
virus infections using 
residual sera/
convenience samples 
for establishing 
baseline seropreva-
lence and/or 
monitoring trends over 
time
Estimate population 
humoral immune status/
susceptibility to currently 
circulating seasonal 
influenza virus strains 
Estimate incidence in 
previous seasons for 
different influenza virus 
strains
Age and demographic 
factors known in 
advance; least resource 
intensive of all protocols; 
samples are already 
collected
Population characteristics 
(age, gender, comorbidi-
ties) may be restricted; 
mostly cross- sectional; 
cannot provide individual 
infection rates@@
Interpretation of 
laboratory results (e.g., 
seroincidence is 
challenging)
Sera can be collected 
anytime
Zoonotic influenza viruses or emerging respiratory viruses
Investigation of 
zoonotic influenza A 
virus infections in 
humans
Measure age- specific 
serologic evidence of 
infection in relation to 
zoonotic exposures 
Identify the risk factors 
for human infection by 
novel influenza A viruses
Age- specific infection 
rates (zoonotic 
exposure); can identify 
modifiable risk factors; 
can quantify the 
proportion of asympto-
matic infections; assesses 
the potential human- to- 
human transmission; 
comparative analysis of 
human and animal 
influenza A viral strains
Subject to outbreak 
unpredictability 
(planning); may be 
politically charged 
environment; location 
may be hard to reach; 
source of infection could 
be in a complex and 
diverse ecosystem; need 
to coordinate with animal 
health authorities
Important: 4–6 wk after 
confirmed outbreak with 
optional longitudinal 
follow- up every 6 wk 
until outbreak is over
aCONSISE protocols are available here: https://consise.tghn.org/articles/.
T A B L E  1  (Continued)
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nd
 t
he
 s
ou
rc
es
 a
nd
 
m
et
ho
ds
 o
f s
el
ec
ti
on
 o
f p
ar
ti
ci
pa
nt
s
(b
). 
 C
oh
or
t 
st
ud
y—
Fo
r 
m
at
ch
ed
 s
tu
di
es
, g
iv
e 
m
at
ch
in
g 
cr
ite
ria
 a
nd
 t
he
 n
um
be
r 
of
 
ex
po
se
d 
an
d 
un
ex
po
se
d 
C
as
e–
co
nt
ro
l s
tu
dy
—
Fo
r 
m
at
ch
ed
 s
tu
di
es
, g
iv
e 
m
at
ch
in
g 
cr
ite
ria
 a
nd
 t
he
 
nu
m
be
r 
of
 c
on
tr
ol
s 
pe
r 
ca
se
R
O
SE
S-
 I 6
.1
: F
or
 c
as
e-
 as
ce
rt
ai
ne
d 
tr
an
sm
is
si
on
 s
tu
di
es
, d
es
cr
ib
e 
th
e 
m
et
ho
d 
of
 c
as
e 
as
ce
rt
ai
nm
en
t 
an
d 
cr
ite
ria
 fo
r 
de
fin
in
g 
a 
“c
as
e”
R
O
SE
S-
 I 6
.2
: F
or
 h
ou
se
ho
ld
-  
or
 in
sti
tu
ti
on
- b
as
ed
 t
ra
ns
m
is
si
on
 s
tu
di
es
, 
de
sc
rib
e 
th
e 
de
fin
iti
on
 o
f a
 h
ou
se
ho
ld
 o
r 
th
e 
in
sti
tu
ti
on
R
O
SE
S-
 I 6
.3
: F
or
 o
ut
br
ea
k 
in
ve
sti
ga
ti
on
s 
in
vo
lv
in
g 
se
ro
lo
gi
c 
sa
m
pl
in
g,
 
de
sc
rib
e 
th
e 
se
tti
ng
 in
 w
hi
ch
 t
he
 c
as
es
 w
er
e 
id
en
ti
fie
d,
 fo
r 
ex
am
pl
e,
 v
ill
ag
e/
re
si
de
nti
al
 s
etti
ng
, o
cc
up
ati
on
al
 w
or
kp
la
ce
R
O
SE
S-
 I 6
.4
: T
o 
ai
d 
th
e 
in
te
rp
re
ta
ti
on
 o
f s
er
oe
pi
de
m
io
lo
gi
c 
st
ud
ie
s 
of
 n
ov
el
 
in
flu
en
za
 A
 v
iru
s 
su
bt
yp
es
, t
he
 r
es
ul
ts
 fr
om
 e
xp
os
ed
 p
op
ul
ati
on
s 
sh
ou
ld
 b
e 
co
m
pa
re
d 
w
ith
 t
he
 r
es
ul
ts
 fr
om
 u
ne
xp
os
ed
 p
op
ul
ati
on
s.
 E
ff
or
ts
 t
o 
va
lid
at
e 
th
e 
as
sa
y 
in
 v
iro
lo
gi
ca
lly
 c
on
fir
m
ed
 c
as
es
 s
ho
ul
d 
be
 r
ep
or
te
d
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Ite
m
Ite
m
 
nu
m
be
r
ST
RO
BE
 it
em
s
R
O
SE
S-
 I i
te
m
s
V
ar
ia
bl
es
7
C
le
ar
ly
 d
efi
ne
 a
ll 
ou
tc
om
es
, e
xp
os
ur
es
, p
re
di
ct
or
s,
 p
ot
en
ti
al
 r
is
k 
fa
ct
or
s,
 a
nd
 e
ff
ec
t 
m
od
ifi
er
s.
 G
iv
e 
di
ag
no
sti
c 
cr
ite
ria
, i
f a
pp
lic
ab
le
R
O
SE
S-
 I 7
.1
 T
he
 m
ed
ia
n 
ag
e 
an
d 
ra
ng
e 
fo
r 
ea
ch
 e
xp
os
ur
e 
gr
ou
p 
sh
ou
ld
 b
e 
re
po
rt
ed
R
O
SE
S-
 I 7
.2
: D
es
cr
ib
e 
th
e 
po
te
nti
al
 fo
r 
im
m
un
iz
ati
on
 (s
pe
ci
fy
 v
ac
ci
ne
 a
nd
 
ti
m
in
g 
of
 v
ac
ci
na
ti
on
 in
 r
el
ati
on
sh
ip
 t
o 
co
lle
cti
on
 o
f s
er
um
), 
if 
ap
pl
ic
ab
le
, t
o 
aff
ec
t 
th
e 
ou
tc
om
e 
m
ea
su
re
s
R
O
SE
S-
 I 7
.3
: D
es
cr
ib
e 
an
y 
kn
ow
n 
or
 p
ot
en
ti
al
 im
m
un
ol
og
ic
al
 c
ro
ss
- r
ea
cti
vi
ty
 
th
at
 m
ay
 b
ia
s 
th
e 
ou
tc
om
e 
m
ea
su
re
s
R
O
SE
S-
 I 7
.4
: D
es
cr
ib
e 
ill
ne
ss
 d
efi
ni
ti
on
s 
an
d 
m
et
ho
ds
 fo
r 
as
ce
rt
ai
ni
ng
 t
he
 
pr
es
en
ce
 o
r 
ab
se
nc
e 
of
 c
lin
ic
al
 il
ln
es
s 
in
 s
ub
je
ct
s
D
at
a 
so
ur
ce
s/
m
ea
su
re
m
en
t b
ia
se
s
8a
Fo
r 
ea
ch
 v
ar
ia
bl
e 
of
 in
te
re
st
, g
iv
e 
so
ur
ce
s 
of
 d
at
a 
an
d 
de
ta
ils
 o
f m
et
ho
ds
 o
f 
as
se
ss
m
en
t 
(m
ea
su
re
m
en
t)
. D
es
cr
ib
e 
co
m
pa
ra
bi
lit
y 
of
 a
ss
es
sm
en
t 
m
et
ho
ds
 if
 
th
er
e 
is 
m
or
e 
th
an
 o
ne
 g
ro
up
R
O
SE
S-
 I 8
.1
: I
f r
el
ev
an
t, 
de
sc
rib
e 
m
ea
su
re
s 
ta
ke
n 
to
 id
en
ti
fy
 a
nd
 r
ec
or
d 
im
m
un
iz
ati
on
 h
is
to
ry
B
ia
s
9
D
es
cr
ib
e 
an
y 
eff
or
ts
 t
o 
ad
dr
es
s 
th
e 
po
te
nti
al
 s
ou
rc
es
 o
f b
ia
s
R
O
SE
S-
 I 9
.1
: I
f r
el
ev
an
t, 
de
sc
rib
e 
eff
or
ts
 t
o 
co
nt
ro
l f
or
 t
he
 p
ot
en
ti
al
 e
ff
ec
t 
of
 
im
m
un
iz
ati
on
 o
n 
es
ti
m
at
es
 o
f o
ut
co
m
es
St
ud
y 
si
ze
10
Ex
pl
ai
n 
ho
w
 t
he
 s
tu
dy
 s
iz
e 
w
as
 a
rr
iv
ed
 a
t
R
O
SE
S-
 I 1
0.
1:
 D
es
cr
ib
e 
th
e 
ba
se
lin
e 
es
ti
m
at
ed
 s
er
op
re
va
le
nc
e 
at
 g
iv
en
 
an
ti
bo
dy
 ti
te
rs
 o
r 
in
ci
de
nc
e 
of
 in
fe
cti
on
 a
nd
 c
ite
 p
ub
lis
he
d 
lit
er
at
ur
e 
to
 
su
pp
or
t 
th
es
e 
es
ti
m
at
es
Q
ua
nti
ta
ti
ve
 v
ar
ia
bl
es
11
Ex
pl
ai
n 
ho
w
 q
ua
nti
ta
ti
ve
 v
ar
ia
bl
es
 w
er
e 
ha
nd
le
d 
in
 t
he
 a
na
ly
se
s.
 If
 a
pp
lic
ab
le
, 
de
sc
rib
e 
w
hi
ch
 g
ro
up
in
gs
 w
er
e 
ch
os
en
, a
nd
 w
hy
R
O
SE
S-
 I 1
1.
1:
 D
es
cr
ib
e 
th
e 
se
ro
lo
gi
ca
l a
ss
ay
’s
 li
m
it 
of
 d
et
ec
ti
on
 a
nd
 h
ow
 
th
is
 li
m
it 
is
 d
efi
ne
d 
or
 c
al
cu
la
te
d.
 D
es
cr
ib
e 
ho
w
 s
am
pl
es
 w
ith
 a
 r
es
ul
t 
be
lo
w
 
or
 o
n 
th
e 
bo
rd
er
lin
e 
of
 t
he
 li
m
it 
w
er
e 
ha
nd
le
d 
in
 t
he
 a
na
ly
si
s
R
O
SE
S-
 I 1
1.
2:
 D
es
cr
ib
e 
an
d 
ju
sti
fy
 t
he
 ti
te
r 
or
 o
th
er
 r
es
ul
t 
us
ed
 t
o 
de
fin
e 
“s
er
op
os
iti
vi
ty
,” 
or
 t
he
 a
nti
bo
dy
 ti
te
r 
ch
an
ge
 o
r 
ch
an
ge
 in
 o
th
er
 a
ss
ay
 r
es
ul
t 
us
ed
 t
o 
de
fin
e 
“s
er
oc
on
ve
rs
io
n.
” 
A
vo
id
 t
he
 t
er
m
 “
se
ro
co
nv
er
si
on
” 
un
le
ss
 
re
fe
rr
in
g 
to
 c
ha
ng
e 
fr
om
 u
nd
et
ec
ta
bl
e 
to
 d
et
ec
ta
bl
e 
an
ti
bo
dy
 le
ve
l. 
O
th
er
w
is
e 
re
po
rt
 t
he
 fo
ld
- r
is
e 
in
 ti
te
r. 
A
vo
id
 t
he
 t
er
m
 “
in
fe
cti
on
” 
bu
t 
re
po
rt
 
“s
er
op
re
va
le
nc
e 
at
 a
 ti
te
r 
of
 …
.”
R
O
SE
S-
 I 1
1.
3:
 If
 s
ta
te
m
en
ts
 o
r 
in
fe
re
nc
es
 a
re
 m
ad
e 
ab
ou
t 
pr
ot
ec
ti
on
 fr
om
 
in
fe
cti
on
, d
es
cr
ib
e 
w
ha
t 
is
 k
no
w
n 
ab
ou
t 
th
e 
co
rr
el
ati
on
 b
et
w
ee
n 
th
e 
as
sa
y 
re
su
lts
 a
nd
 p
ro
te
cti
on
 fr
om
 in
fe
cti
on
 a
nd
 il
ln
es
s
St
ati
sti
ca
l m
et
ho
ds
12
(a
). 
D
es
cr
ib
e 
al
l s
ta
ti
sti
ca
l m
et
ho
ds
, i
nc
lu
di
ng
 t
ho
se
 u
se
d 
to
 c
on
tr
ol
 fo
r 
co
nf
ou
nd
in
g
(b
). 
D
es
cr
ib
e 
an
y 
m
et
ho
ds
 u
se
d 
to
 e
xa
m
in
e 
su
bg
ro
up
s 
an
d 
in
te
ra
cti
on
s
(c
). 
Ex
pl
ai
n 
ho
w
 m
is
si
ng
 d
at
a 
w
er
e 
ad
dr
es
se
d
(d
). 
 C
oh
or
t 
st
ud
y—
If
 a
pp
lic
ab
le
, e
xp
la
in
 h
ow
 lo
ss
 t
o 
fo
llo
w
 u
p 
w
as
 a
dd
re
ss
ed
 
C
as
e–
co
nt
ro
l s
tu
dy
—
If
 a
pp
lic
ab
le
, e
xp
la
in
 h
ow
 m
at
ch
in
g 
of
 c
as
es
 a
nd
 c
on
tr
ol
s 
w
as
 a
dd
re
ss
ed
 
C
ro
ss
-s
ec
ti
on
al
 s
tu
dy
—
If
 a
pp
lic
ab
le
, d
es
cr
ib
e 
an
al
yti
ca
l m
et
ho
ds
 t
ak
in
g 
ac
co
un
t 
of
 s
am
pl
in
g 
st
ra
te
gy
(e
). 
D
es
cr
ib
e 
an
y 
se
ns
iti
vi
ty
 a
na
ly
se
s
R
O
SE
S-
 I 1
2.
1:
 if
 r
el
ev
an
t, 
st
at
e 
ho
w
 t
he
 n
on
- in
de
pe
nd
en
ce
 o
f d
at
a 
w
as
 
m
an
ag
ed
R
O
SE
S-
 I 1
2.
2:
 if
 r
el
ev
an
t, 
re
po
rt
 m
et
ho
ds
 u
se
d 
to
 a
cc
ou
nt
 fo
r 
th
e 
pr
ob
ab
ili
ty
 
of
 s
er
op
os
iti
vi
ty
 o
r 
se
ro
co
nv
er
si
on
 if
 in
fe
ct
ed
, a
nd
 t
o 
ac
co
un
t 
fo
r 
de
ca
y 
in
 
an
ti
bo
dy
 ti
te
rs
 o
ve
r 
ti
m
e
T
A
B
LE
 2
 (C
on
tin
ue
d)
(C
on
tin
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Ite
m
Ite
m
 
nu
m
be
r
ST
RO
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 it
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s
R
O
SE
S-
 I i
te
m
s
La
bo
ra
to
ry
 m
et
ho
ds
12
a
Sa
m
pl
e 
ty
pe
 a
nd
 
ha
nd
lin
g
R
O
SE
S-
 I 1
2a
.1
: D
es
cr
ib
e 
th
e 
sa
m
pl
e 
ty
pe
—
se
ru
m
 o
r 
pl
as
m
a.
 If
 p
la
sm
a 
is
 
us
ed
, s
pe
ci
fy
 t
he
 a
nti
co
ag
ul
an
t 
us
ed
 (h
ep
ar
in
, s
od
iu
m
 c
itr
at
e,
 E
D
TA
, e
tc
.)
R
O
SE
S-
 I 1
2a
.2
: D
es
cr
ib
e 
th
e 
sp
ec
im
en
 s
to
ra
ge
 c
on
di
ti
on
s 
(4
°C
, −
20
 °
C
, −
80
 
°C
). 
If
 fr
oz
en
 p
rio
r 
to
 t
he
 a
na
ly
si
s,
 d
es
cr
ib
e 
th
e 
ti
m
e 
to
 fr
ee
zi
ng
 a
nd
 t
he
 
nu
m
be
r 
of
 fr
ee
ze
/t
ha
w
 c
yc
le
s 
pr
io
r 
to
 t
es
ti
ng
Se
ro
lo
gi
ca
l a
ss
ay
s
R
O
SE
S-
 I 1
2a
.3
: S
pe
ci
fy
 t
he
 a
ss
ay
 t
yp
e 
(e
.g
., 
he
m
ag
gl
uti
na
ti
on
 in
hi
bi
ti
on
; 
vi
ru
s 
ne
ut
ra
liz
ati
on
/m
ic
ro
ne
ut
ra
liz
ati
on
; E
LI
SA
; o
th
er
) a
nd
 m
et
ho
ds
 u
se
d 
to
 
de
te
rm
in
e 
th
e 
en
dp
oi
nt
 ti
te
r
R
O
SE
S-
 I 1
2a
.4
: R
ef
er
en
ce
 a
 p
re
vi
ou
sl
y 
pu
bl
is
he
d,
 C
O
N
SI
SE
 c
on
se
ns
us
 
se
ro
lo
gi
c 
as
sa
y 
or
 W
H
O
 p
ro
to
co
l i
f u
se
d,
 a
nd
 a
ny
 m
od
ifi
ca
ti
on
s 
of
 t
he
 
pr
ot
oc
ol
. I
f a
 p
re
vi
ou
sl
y 
pu
bl
is
he
d 
pr
ot
oc
ol
 is
 n
ot
 u
se
d,
 p
ro
vi
de
 fu
ll 
de
ta
ils
 
in
 s
up
pl
em
en
ta
ry
 m
at
er
ia
ls
R
O
SE
S-
 I 1
2a
.5
: S
ta
te
 w
ha
t 
is
 k
no
w
n 
ab
ou
t 
th
e 
de
te
rm
in
an
ts
 o
f t
he
 v
ar
ia
bi
lit
y 
of
 t
he
 a
nti
bo
dy
 d
et
ec
ti
on
 a
ss
ay
 b
ei
ng
 u
se
d
R
O
SE
S-
 I 1
2a
.6
: S
pe
ci
fy
 t
he
 a
nti
ge
n(
s)
 u
se
d 
in
 t
he
 a
ss
ay
, i
nc
lu
di
ng
 v
iru
s 
st
ra
in
 
na
m
e,
 s
ub
ty
pe
, l
in
ea
ge
 o
r 
cl
ad
e,
 w
ith
 s
ta
nd
ar
di
ze
d 
no
m
en
cl
at
ur
e 
an
d 
re
fe
re
nc
e;
 s
pe
ci
fy
 w
he
th
er
 li
ve
 v
iru
s 
or
 in
ac
ti
va
te
d 
vi
ru
s 
w
as
 u
se
d 
(w
he
re
 
ap
pl
ic
ab
le
)
R
O
SE
S-
 I 1
2a
.7
: R
ep
or
t 
if 
an
ti
ge
n(
s)
 fr
om
 p
ot
en
ti
al
ly
 c
ro
ss
- r
ea
cti
ve
 
pa
th
og
en
s/
st
ra
in
s 
w
er
e 
us
ed
 in
 o
rd
er
 t
o 
id
en
ti
fy
 c
ro
ss
- r
ea
cti
vi
ty
, a
nd
 
sp
ec
ify
 w
hi
ch
 a
nti
ge
n 
w
as
 u
se
d,
 in
cl
ud
in
g 
vi
ru
s 
na
m
e,
 s
ub
ty
pe
, s
tr
ai
n,
 
lin
ea
ge
 a
nd
 c
la
de
, w
ith
 s
ta
nd
ar
di
ze
d 
no
m
en
cl
at
ur
e 
an
d 
re
fe
re
nc
e
R
O
SE
S-
 I 1
2a
.8
: I
f r
ed
 b
lo
od
 c
el
ls
 w
er
e 
us
ed
 fo
r 
a 
he
m
ag
gl
uti
ni
n 
in
hi
bi
ti
on
 
as
sa
y,
 s
pe
ci
fy
 t
he
 a
ni
m
al
 s
pe
ci
es
 fr
om
 w
hi
ch
 t
he
y 
w
er
e 
ob
ta
in
ed
 a
nd
 
co
nc
en
tr
ati
on
 (v
/v
) u
se
d
R
O
SE
S-
 I 1
2a
.9
: D
es
cr
ib
e 
po
si
ti
ve
 a
nd
 n
eg
ati
ve
 c
on
tr
ol
s 
us
ed
R
O
SE
S-
 I 1
2a
.1
0:
 D
es
cr
ib
e 
st
ar
ti
ng
 a
nd
 e
nd
 d
ilu
ti
on
s
R
O
SE
S-
 I 1
2a
.1
1:
 S
pe
ci
fy
 la
bo
ra
to
ry
 b
io
sa
fe
ty
 c
on
di
ti
on
s
R
O
SE
S-
 I 1
2a
.1
2:
 S
pe
ci
fy
 w
he
th
er
 r
ep
lic
ati
on
 w
as
 p
er
fo
rm
ed
, a
nd
 if
 s
o,
 t
he
 
ac
ce
pt
ab
le
 r
ep
lic
ati
on
 p
ar
am
et
er
s
R
O
SE
S-
 I 1
2a
.1
3:
 S
pe
ci
fy
 w
he
th
er
 a
 c
on
fir
m
at
or
y 
as
sa
y 
w
as
 p
er
fo
rm
ed
 a
nd
 
al
l s
pe
ci
fic
s 
of
 t
hi
s 
as
sa
y,
 a
t 
th
e 
sa
m
e 
le
ve
l o
f d
et
ai
l
R
O
SE
S-
 I 1
2a
.1
4:
 S
pe
ci
fy
 in
te
rn
ati
on
al
 s
ta
nd
ar
ds
 u
se
d,
 if
 a
pp
ro
pr
ia
te
T
A
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a
(a
). 
 R
ep
or
t 
th
e 
nu
m
be
rs
 o
f i
nd
iv
id
ua
ls
 a
t 
ea
ch
 s
ta
ge
 o
f t
he
 s
tu
dy
—
th
e 
nu
m
be
rs
 
po
te
nti
al
ly
 e
lig
ib
le
, e
xa
m
in
ed
 fo
r 
el
ig
ib
ili
ty
, c
on
fir
m
ed
 e
lig
ib
le
, i
nc
lu
de
d 
in
 t
he
 
st
ud
y,
 c
om
pl
eti
ng
 fo
llo
w
-u
p,
 a
nd
 a
na
ly
ze
d
(b
). 
G
iv
e 
re
as
on
s 
fo
r 
no
n-
pa
rti
ci
pa
ti
on
 a
t 
ea
ch
 s
ta
ge
(c
). 
C
on
si
de
r 
us
e 
of
 a
 fl
ow
 d
ia
gr
am
Se
e 
ST
R
O
B
E 
ite
m
D
es
cr
ip
ti
ve
 d
at
a
14
a
(a
). 
 G
iv
e 
ch
ar
ac
te
ris
ti
cs
 o
f s
tu
dy
 p
ar
ti
ci
pa
nt
s 
(e
.g
., 
de
m
og
ra
ph
ic
, c
lin
ic
al
, s
oc
ia
l) 
an
d 
in
fo
rm
ati
on
 o
n 
ex
po
su
re
s 
an
d 
po
te
nti
al
 r
is
k 
fa
ct
or
s
(b
). 
In
di
ca
te
 t
he
 n
um
be
r 
of
 p
ar
ti
ci
pa
nt
s 
w
ith
 m
is
si
ng
 d
at
a 
fo
r 
ea
ch
 v
ar
ia
bl
e 
of
 
in
te
re
st
(c
). 
C
oh
or
t 
st
ud
y—
su
m
m
ar
iz
e 
fo
llo
w
-u
p 
ti
m
e 
(e
.g
., 
av
er
ag
e 
an
d 
to
ta
l a
m
ou
nt
)
Se
e 
ST
R
O
B
E 
ite
m
O
ut
co
m
e 
da
ta
15
a
C
oh
or
t 
st
ud
y—
re
po
rt
 t
he
 n
um
be
rs
 o
f o
ut
co
m
e 
ev
en
ts
 o
r 
su
m
m
ar
y 
m
ea
su
re
s 
ov
er
 
ti
m
e 
C
as
e–
co
nt
ro
l s
tu
dy
—
re
po
rt
 t
he
 n
um
be
rs
 in
 e
ac
h 
ex
po
su
re
 c
at
eg
or
y,
 o
r 
su
m
m
ar
y 
m
ea
su
re
s 
of
 e
xp
os
ur
e 
C
ro
ss
- s
ec
ti
on
al
 s
tu
dy
—
re
po
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of populations in specific settings, such as households, healthcare set-
tings, or other confined settings (such as military units, child/elderly 
care centers or prisons), to estimate the risk of secondary virus infec-
tions or to estimate the seroprevalence of antibodies in specific popu-
lations. The specific measure of occurrence that is being estimated 
(e.g., point seroprevalence, cumulative incidence, secondary infection 
risk) should be described in the introduction [ROSES- I 3.1].
3.1.3 | Epidemiological methods
Study design and setting
A number of different seroepidemiologic study designs can be used 
to estimate various measures of virus infection risk, and different 
designs have different strengths and weaknesses depending on the 
objectives of the investigation (Table 1). The methods section should 
begin by describing the study design, the study population, sam-
pling procedures (e.g., random or convenience), the source of serum 
or plasma that was analyzed (e.g., frozen stored vs recently collected 
and tested), the rationale for choosing the study design, and the gen-
eralizability beyond the study population [ROSES- I 4.1]. Inferences 
about the probability of prior or recent virus infection based on the 
titer of antibody in a single serum sample, or changes in the titer of 
antibody in sequential serum samples, are based upon assumptions 
about the kinetics of antibody titers following virus infection. In order 
for readers to assess or test the validity of the assumed relationship, it 
is important that details are provided of the actual or likely period of 
exposure(s) to the circulating virus strain and infection risk in relation 
to the time point that the serum samples are taken [ROSES- I 5.1- 5.3]. 
For example, an overly short (<14 days) or overly long (>6 months) 
interval between exposure(s) and serum sampling will increase the 
probability of uninterpretable results because antibody titers may not 
yet have reached a maximum titer, or may have decayed below the 
seroprevalence or seroconversion titer detection thresholds set to 
define infection retrospectively.
Participants
For studies where close contacts of confirmed influenza cases (e.g., 
household contacts of confirmed cases; Table 1: household transmis-
sion studies) are monitored for seroconversion in order to estimate 
the incidence of secondary infections, in addition to the STROBE 
criteria for reporting study subject details, the method and criteria 
for identifying index case patients should be reported because the 
probability of onward transmission may vary according to the char-
acteristics of the index case patients (Table 2). Thus, comparison of 
the results of different case- ascertained virus transmission studies 
requires this information [ROSES- I 6.1]. For example, subjects with 
a clinical illness that is severe enough to seek medical care, or those 
with preexisting comorbid conditions, immunosuppression, or with 
poorly developed immune systems (e.g., young infants), may be more 
infectious than mild case patients detected through active follow- 
up of case contacts. Similarly, the virus load in clinical specimens, 
and therefore infectivity, may differ among subjects with infections 
detected by virus culture, molecular diagnostic techniques, or rapid 
antigen detection point- of- care (POC) diagnostic tests. In addition, 
the duration, intensity, and route of exposure during the index case 
patient’s illness will influence the infectiousness of the index case 
patient to close contacts. For studies of virus infection transmission 
risk in households or closed settings, or for outbreak investigations, 
the definition of the setting being studied (e.g., how a household was 
defined) should be described in order to permit comparison with 
other similar studies [ROSES- I 6.2- 6.3]. The results of seroepidemio-
logic studies among humans of antibodies to novel avian influenza 
viruses (AIVs) have sometimes been challenging to interpret, because 
it is difficult to distinguish the detection of low titers of virus- specific 
antibodies from the detection of low titers of cross- reactive antibod-
ies. As such, seroepidemiologic surveys of novel AIVs should ideally 
compare the seroprevalence in exposed populations to the seroprev-
alence in populations who have likely not been exposed to the ani-
mal reservoir or to sick human case patients, and should report the 
efforts to validate the assay in virologically confirmed cases [ROSES- I 
6.4].11,15,26
Variables, data sources, and bias
Age is an important determinant of serologic responses to virus infec-
tion, and therefore, it is critical that the median and range of the age 
of participants, overall and by subgroup (study subjects and control 
population; the control group should have a similar median age and 
age range to the study group.), should be reported (ROSES- I 7.1). For 
influenza, antibody may be present as a result of immunization. It is 
therefore essential that where a vaccine exists, details are provided 
of the vaccine(s) used in the study population, when vaccination was 
administered in relation to the timing of sample collection during the 
investigation [ROSES- I 7.2], the methods used to identify and record 
vaccination history [ROSES- I 8.1], as well as statistical methods used 
to control for the potential effect of immunization [ROSES- I 9.1]. 
When no data are available on vaccination in the study population or 
the general population from which the study participants were cho-
sen, this should be stated clearly along with any anecdotal informa-
tion as to the presence or absence of vaccination during the period 
of study. When pathogens share similar antigenic epitopes, antibody 
assays may detect cross- reactivity to more than one pathogen. For 
example, antibodies that cross- reacted with the influenza A(H1N1)
pdm09 virus were detected in serum samples collected prior to the 
emergence of the 2009 H1N1 pandemic virus. These cross- reactive 
antibodies were typically found in older people who were exposed 
to earlier influenza A(H1N1) viruses, particularly the 1918 H1N1 
virus.27 Therefore, any known or potential immunological cross- 
reactivity and efforts to detect and control for cross- reactivity should 
also be reported [ROSES- I 7.3; 12a.7]. Influenza virus infection can 
result in a wide range of clinical outcomes, from asymptomatic infec-
tion to a rapidly progressive fatal illness. Different definitions of 
clinical illness and different methods of ascertaining the presence or 
absence of clinical illness will have variable sensitivity and specific-
ity for detecting an influenza- associated illness. The definitions and 
methods used to identify the clinical outcomes should be described 
[ROSES- I 7.4].
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Study subjects and sample size
In order to permit the generalizability of the study results, it is prefer-
able that the study population be as close as possible to the general 
population under study. However, this is not always feasible, and for 
example, many serologic studies detecting antibodies to A(H1N1)
pdm09 virus infection were conducted using residual sera from blood 
donors4,28 or hospitalized patients,29 who may not be representa-
tive of the broader populations in those locations. The potential to 
introduce selection bias into the study should be addressed in the 
discussion. Any method used to infer cumulative incidence of infec-
tion among the population based on results from the study sample, 
for example, weighting or standardization, should be reported in suf-
ficient detail to permit reproducibility (ROSES- I 16.2).
In addition, the confidence in the results and conclusions of any 
seroepidemiologic study depends, among other things, on whether 
the planned study sample size was sufficient to provide estimates of 
prevalence or incidence of infection with sufficient precision and cer-
tainty.30 To assess whether the planned sample size was adequate, the 
assumed baseline prevalence of given antibody titers or the baseline 
cumulative incidence of a given change in antibody titer should be 
reported [ROSES- I 10.1]. Differences between the planned and actual 
sample size should also be reported, and any differences explained.
Quantitative variables
For seroepidemiologic studies, it is particularly important that full 
details and conditions of assay methods to detect antibodies are 
reported including the upper and lower limits (antibody dilution range) 
of assay detection. In addition, variable conditions of the assays should 
be described. The minimum detection level of the assay, and how this 
limit is defined or calculated, should be reported, as should the han-
dling in the analysis of samples with a result below or on the border-
line of the minimum detection level [ROSES- I 11.1]. A result below the 
minimum detection level of the assay is consistent with an antibody 
titer of anywhere between zero and just below the limit of detection. 
How these titers are analyzed and interpreted can affect the results, 
especially if they constitute a large proportion of the results. A com-
mon convention, which is acceptable, is to consider a result below 
the limit of detection as a serial step below that limit; that is, if the 
starting antibody dilution is 10, then a value of <10 can be reported 
as a five for the purposes of data analysis rather than a zero or a “not 
detected.” Similarly, antibody titer thresholds to define a seropositive 
result are critically important yet are, in some studies, fairly arbitrary. 
Thresholds that are designed with high specificity for diagnostic pur-
poses in the cases of clinical illness may not provide reliable estimates 
of virus infection rates at the population level, if specificity has been 
optimized at the expense of sensitivity.31 Therefore, the criterion for 
defining a positive result (as either an indication of prior infection or to 
infer protection) and the justification for using this criterion in the par-
ticular study setting must be reported [ROSES- I 11.2]. Immunological 
correlates of protection from influenza virus infection and illness are 
difficult to establish and the relationship between antibody titer and 
protection is not binary (completely protected above a titer threshold 
and completely unprotected below the threshold).32,33 Therefore, if 
results are used to make inferences about the proportion of a popula-
tion or population subgroup that are “protected,” it is important that 
this is justified by reference to what is known about the correlation 
between antibody titers measured by the specific assay and protec-
tion from infection or illness [ROSES- I 11.3].
Statistical methods and presentation of results
In cross- sectional studies, seroprevalence can be estimated by the 
proportion of specimens with antibody titers at or above a specific 
threshold, with 95% confidence intervals typically obtained using the 
binomial formula or the normal approximation to the binomial. If a 
number of additional assumptions are met, including that seroprev-
alence before an epidemic is very low, and almost all infected indi-
viduals have rises in convalescent antibody titers above the chosen 
threshold, the post- epidemic seroprevalence can provide an approxi-
mate estimate of the cumulative incidence of infection.34 Note that 
seroprevalence is a proportion and not a rate.
In studies with paired sera, the cumulative incidence of virus infec-
tion can be estimated by the proportion of persons with a rise in anti-
body titer, traditionally a fourfold or greater rise.31 In most studies, 
95% confidence intervals are typically estimated using the binomial 
formula or the normal approximation to the binomial, implicitly assum-
ing that each person can experience no more than one virus infection 
during the period considered. It is noteworthy to point out also that 
cumulative incidence of virus infection is sometimes referred to as 
an “attack rate,” although a proportion of infections may be asymp-
tomatic (and therefore not “attacks”), and the quantity measured is a 
proportion and not a rate. The term “cumulative incidence of infec-
tion” should therefore be preferred to “attack rate” in the context of 
serological studies.
In either case, the methods used to account for the probability 
of seropositivity or seroconversion if infected, and any method used 
to account for decay in antibody titer over time, should be reported 
(ROSES- I 12.2). To increase transparency of cumulative incidence of 
infection estimates, it is often helpful to report unadjusted estimates 
of the distribution of antibody titers by age group (ROSES- I 16.1).
In some studies, particularly those with more complex designs in 
terms of timing of serologic measurements, improved estimates of the 
seroprevalence at a certain point in time, or the cumulative incidence 
of infection over a specified time period, may be obtained by fitting 
observed data to a mechanistic model of transmission dynamics.4,35 
This can account for non- independence in the data (ROSES- I 12.1).
3.1.4 | Laboratory methods
Sample type and handling
Although serum samples are more commonly used for serologic stud-
ies, convenience sampling may only enable access to plasma. The use 
of anticoagulants to separate plasma has been shown to reduce the 
antibody titer to some influenza viruses.36 Thus, defining the sample 
type and anticoagulant, if used, is necessary (ROSES- I 12a.1). The 
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storage conditions, duration, and subsequent treatment of samples 
(e.g., temperature and the number of freeze/thaw cycles) are impor-
tant to report, if known, as repeated freeze/thaw cycles may also 
reduce the antibody titer (ROSES- I 12a.2).
Serologic assays
Where possible, standard serologic assays [e.g., hemagglutination 
inhibition (HAI) assay to detect HAI antibodies or microneutraliza-
tion (MN) assay to detect neutralizing antibodies for influenza virus-
es] should be used.37All specimen preparation and assay protocols 
should be provided, either referenced to a published protocol, with 
any changes specified, or as detailed methodology for novel serologic 
assays (ROSES- I 12a.3, 4). Any parameters that may induce variability 
of the antibody detection assay being used should be stated (ROSES- I 
12a.5). It is necessary to report all details of the antigen used, includ-
ing the virus name, subtype, strain, lineage or clade as well as prepa-
ration type (e.g., live virus, inactivated virus, recombinant protein). 
This antigen should be antigenically equivalent to the specific virus 
strain to which the study population was exposed. To enable the 
comparison between laboratories and also aid in the development of 
the specific serologic assay in other laboratories, all detection param-
eters (red blood cell species and concentration (as percent v/v), ELISA 
substrate, starting and end dilutions, etc.), the number of replicates 
performed and controls, as well as biosafety requirements, should be 
reported (ROSES- I 12a.6, 12a.8- 12a.10, 12a.11). The definition and 
method of endpoint titer calculation should be stated. Interpretation 
of the data is reliant on appropriate description of the limitations of 
each serologic assay (ROSES- I 12a.5) and the reproducibility of the 
assay (ROSES- I 12a.12). Performance of additional serological assays 
to confirm or calibrate results, if appropriate, should be included. 
Specifically, as the WHO recommendation for A(H5N1) viruses rec-
ommends the use of confirmatory serologic assays upon the detection 
of single serum positive by MN assay, any confirmatory assays used 
and the criteria for positivity also need to be described in the same 
details as above (ROSES- I 12a.13).38,39 Inclusion of available interna-
tional standards40,41 facilitates the comparability of serological data. 
Inclusion of the actual titers obtained from the international stand-
ards and indication whether the data are reported as raw values or 
international standard- adjusted values should therefore be described 
(ROSES- I 12a.14).
Results
Unadjusted estimates of titers by age group should be reported 
(ROSES- I 16.1) and where the results from the study sample have 
been standardized to a general or target population, the method of 
standardization should be reported (ROSES- I 16.2).
Discussion
Different seroepidemiologic study designs have different strengths 
and weaknesses, which have been reviewed and summarized by the 
CONSISE group (Table 1). The limitations and strengths of the study 
design being reported should be covered in the discussion (ROSES- I 
19.1). Table 1 may be a useful reference for discussing limitations and 
strengths. Because the interpretation of seroepidemiologic studies is 
critically dependent on the specificity of the assay, in addition to the 
STROBE item, specific attention should be given to the interpretation 
of the results in the context of known or potential cross- reactivity 
[ROSES_I 20.1].
4  | CONCLUSIONS
The direct comparability of influenza seroepidemiologic studies is cur-
rently limited by a lack of standardization across such studies.8 The 
ROSES- I statement aims to improve the quality and transparency 
of the reporting of such studies so that such studies can be better 
assessed and understood. Here, we have outlined which methodologi-
cal details―study design, study population, epidemiologic data collec-
tion, specimen collection and handling methods, laboratory methods, 
justification of criteria for seropositivity, reporting of results, limita-
tions and biases, and interpretation―should be included when report-
ing the findings of seroepidemiologic studies.
Our aim is for the ROSES- I, like other standards of reporting (e.g., 
CONSORT, STROBE), to be developed and accepted as the standard 
for reporting of influenza seroepidemiologic studies. When nov-
el influenza A viruses emerge, a rapid and robust evaluation of the 
implications of seroepidemiologic studies is critical in order to fully 
assess the population health risks and the need for mitigation mea-
sures. Without the ROSES- I- recommended information for reporting, 
our ability to interpret seroepidemiologic studies of novel influenza A 
viruses will be limited.
This is the first version of the ROSES- I checklist, and we hope this 
will be refined with use and feedback. The approach used by CONSISE 
for influenza seroepidemiologic studies and the items outlined in this 
statement are likely to be applicable or adaptable to other emerging 
respiratory viruses, such as Middle East respiratory syndrome coro-
navirus (MERS- CoV); however for simplicity, the ROSES- I statement 
described here is focused on influenza viruses. For this reason, we 
have entitled this statement ROSES- I, to allow for extension of the 
acronym ROSES to other such pathogens.
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